Stiles Financial Services Inc Has $5.35 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Stiles Financial Services Inc raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,962 shares of the company’s stock after purchasing an additional 436 shares during the period. Novo Nordisk A/S comprises 1.9% of Stiles Financial Services Inc’s portfolio, making the stock its 9th biggest position. Stiles Financial Services Inc’s holdings in Novo Nordisk A/S were worth $5,354,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. 1620 Investment Advisors Inc. purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Orion Capital Management LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $26,000. Gilliland Jeter Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares during the period. Finally, Halpern Financial Inc. increased its holdings in shares of Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the period. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $107.00 on Friday. The stock has a market capitalization of $480.17 billion, a price-to-earnings ratio of 36.86, a PEG ratio of 1.43 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The stock has a 50-day moving average of $122.65 and a 200 day moving average of $130.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.